Page 27 - D. Cancer biology

Replenishing SOCS3 Suppresses
Pancreatic Cancer Progression

Sukyeong Jeong, Shinyoung Park, Jaehyeon Kim, Chohyun Kim, Mikyung Kim, Youngsil Choi, and Daewoong Jo
SOCS3 Team, Cellivery R&D Institute, Cellivery Therapeutics, Inc., Seoul 03929, Korea

BACKGROUND AIM
Suppressor of cytokine signaling 3 (SOCS3) is a negative regulator
of Janus kinase/signal transducers and activators of transcription The aim of this study is to evaluate a recombinant SOCS3 protein
(JAK/STAT) signaling, through which it plays pivotal roles in cancer engineered to improve cell- and tissue-permeability, iCP-SOCS3,
progression. It suggests therapeutic potential of intracellularly functions as a tumor suppressor in progression of pancreatic
delivery SOCS3 recombinant protein to target tumors that depends cancer.
on JAK/STAT signaling for growth or survival.
METHODS

A recombinant cell-permeable SOCS3 protein with an advanced macromolecule transduction domain (aMTD) and a solubilization domain,
namely improved cell-permeable (iCP)-SOCS3, was purified and investigated that whether it has increased yield, solubility, cell permeability and
biological activities to inhibit pancreatic cancer growth and tumor cell invasive behaviors.

RESULTS

Figure 1. iCP-SOCS3 Shows High Solubility/Yield Figure 4. iCP-SOCS3 Suppresses Tumor Growth in
& High Cell-Permeability Subcutaneous Tumor Xenografts of Pancreatic Cancer Cells
B C A
A D
421 fold

E
B C
D E

Figure 2. iCP-SOCS3 Suppresses Proliferation &
Apoptosis of Pancreatic Cancer Cells
Figure 5. iCP-SOCS3 Suppresses Tumor Growth By inhibiting
A Phosphorylation of STATs in Orthotopic Xenograft Models
A B

B C

Figure 6. iCP-SOCS3 Is Accumulated
In Target Tissue (Pancreatic Tumor) of Tumor-Bearing Mice

Figure 3. iCP-SOCS3 Suppresses Migration & A B
Invasion of Pancreatic Cancer Cells
A B 2.27

CONCLUSION REFERENCES Contact information
These results provide further evidence that Chung et al. (2020) Science Advances, 6: eaba 1193 Minyong Jung
SOCS3 can function as a tumor suppressor Lim et al. (2013) Clinical Cancer Research, 19: 680-690 New Drug & Business Development
and establish intracellular SOCS3 delivery as a Lim et al. (2013) Biomaterials, 34: 6261-6271
potential protein therapy for pancreatic cancer Lim et al. (2012) Molecular Therapy, 20: 1540-1549 Cellivery Therapeutics, Inc.
by negatively regulating JAK/STAT signaling.
Jo et al (2005) Nature Medicine, 11: 892-898 jungmy@cellivery.com
Jo et al (2001) Nature Biotechnology, 19: 929-933 +82-2-3151-8900